nafamostat has been researched along with Thromboembolism in 1 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Thromboembolism: Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nafamostat mesilate was found to increase the bleeding risk in patients receiving venoarterial ECMO." | 1.43 | Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin. ( Choo, SJ; Chung, CH; Jung, SH; Kim, JB; Lee, JW; Lim, JY, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lim, JY | 1 |
| Kim, JB | 1 |
| Choo, SJ | 1 |
| Chung, CH | 1 |
| Lee, JW | 1 |
| Jung, SH | 1 |
1 other study available for nafamostat and Thromboembolism
| Article | Year |
|---|---|
Anticoagulation During Extracorporeal Membrane Oxygenation; Nafamostat Mesilate Versus Heparin.
Topics: Anticoagulants; Benzamidines; Blood Coagulation; Dose-Response Relationship, Drug; Extracorporeal Me | 2016 |